Novartis Just Cruised Past A Buy Point Amid Its Roche, Sanofi Rivalry
Key Points:
- Investor’s Business Daily provides information for educational purposes only and does not offer investment advice or recommendations to buy or sell securities.
- The information is sourced from what are believed to be reliable providers, but accuracy, timeliness, and suitability are not guaranteed.
- Past investment performance is not indicative of future results, and authors or presenters may hold positions in the stocks they discuss.
- The content and data, including real-time prices and ownership information, are subject to change without notice.
- Investor’s Business Daily and related trademarks are owned by Investor’s Business Daily, LLC, with all rights reserved.